Scientists at EPFL and AstraZeneca have developed a method to map the atomic-level structure of amorphous drugs, demonstrated ...

Guidance for the X-TOLE2 Phase 3 epilepsy study shifted from the second half of 2025 to "early next year," reflecting a slight timeline delay. Management's strategic focus remains on advancing ...

The U.S. Centers for Medicare and Medicaid Services (CMS) said on Monday that it would announce a list of 15 drugs eligible ...

The healthcare and medical industries are increasingly integrating artificial intelligence into their operations, ...

OpenAI has reportedly met with officials from the U.S. Food and Drug Administration (FDA) to discuss the use of artificial ...

While Quantum computing has been reported to be five years away for many years now, companies are preparing for it by setting ...

In addition to full-service phase 1-4 clinical development services ... in the clinical development timeline and reduce precious patent-protected time if the drug proves successful and receives ...

"I am excited to welcome Mark to the team. He has a comprehensive command of all phases of drug development and a track record that includes multiple drug approvals. Mark's leadership will be ...

While significant progress has been made in developing treatments for rare diseases—highlighted by the approval of over 800 drugs for orphan diseases since ...